Navigation Links
ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
Date:3/29/2011

mercially known as Cinryze® (C1 Esterase Inhibitor [Human]), is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease.

About Antibody Mediated Rejection

Antibody-mediated rejection is a type of organ transplant rejection that occurs when a patient has antibodies circulating in their blood against the donor organ (i.e. donor specific antibodies, or DSA).  These antibodies can activate the body's own defense mechanism, known as the complement cascade, which in turn causes a complement-mediated destruction of the transplanted organ.  Since there is no approved treatment for AMR, many thousands of renal failure patients that have DSA cannot be transplanted.  Furthermore, over time, all transplant patients can develop DSA and could lose their transplant to a chronic version of antibody/complement-mediated rejection of the transplanted organ.

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by the U.S. FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency. In the E.U., on March 17, 2011., the CHMP adopted a positive opinion for Cinryze for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. The CHMP positive opinion forms the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
2. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
3. ViroPharma Announces Securities Repurchase Program
4. ViroPharma to Participate in Two March Healthcare Conferences
5. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
6. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
7. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
8. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
9. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
10. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
11. ViroPharma To Participate in Two September Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 A lot of discussion in the ... treating  certain illnesses, injuries, or conditions. As medical science advances, ... methods with ones that they consider to be more cutting ... not one textbook method of treatment that stands out as ...
(Date:1/23/2015)...  The Partnership to Fight Chronic Disease (PFCD) released a public opinion ... a new study analyzing the impact of increased cost sharing on ... working to educate policy makers and the public on the costs ... on how the Iowa healthcare exchange could ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... filed suit today against Johnson & Johnson, Inc. and DePuy ... of the DePuy ASR XL Acetabular Hip Replacement System that ... of John David Hart in Fort Worth, Texas, is the ... United States District Court for the Eastern District of Texas ...
... (Becton, Dickinson and Company) (NYSE: BDX ), ... of its acquisition of Accuri Cytometers, Inc., an Ann ... cytometers for researchers. The acquisition expands BD,s ... and helps expand the use of flow cytometry technology ...
Cached Medicine Technology:DePuy Recalled Hip Device Lawsuit Filed in East Texas 2BD Completes Acquisition of Accuri Cytometers, Inc. 2
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... of vegetables and fruits could be worse than abusing alcohol ... ,It has been estimated that the minimum recommended daily ... vegetables at least. ,According to the 2005 ... accounted for a disability adjusted life years (DALY) rating of ...
... Researchers have confirmed that their studies on bacteria that ... widespread and persistent ear infections// that irritate kids, which ... is pointless. ,Otitis media, a condition of ... to visit doctor and or antibiotic prescriptions in the ...
... science and microbiology and molecular genetics, and his colleagues from ... the ability and potential for growing flu virus. , ... production of new human flu vaccines which is cheaper and ... He identified the new cell line while working on the ...
... are taking part in an initiative to gauge if ... people who have suffered a stroke recently//. The MíTICO ... Isquemic Ictus. ,The study included patients from different ... to three months previously. By means of periodical controls, ...
... is working on four vaccines, including those for treating ... currently working on four vaccines for anthrax, dengue, Japanese ... anthrax vaccine have been completed, which is ready for ... told reporters here today., ,The company would also ...
... wireless device that measures the acidity of stomach contents ... of the nose pain and throat discomfort// associated with ... reflux disease. ,However, while the new technology ... was better for diagnosing or managing these patients, said ...
Cached Medicine News:Health News:‘Biofilms’-Clumped Bacterial Slime Cause Ear Infecti 2Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:New Reflux Disease Technology More Comfortable, Not More Effective 2Health News:New Reflux Disease Technology More Comfortable, Not More Effective 3
The CdTOX A OIA gets the results you need without specimen extraction or instrumentation. Results are available in minutes vs hours or days for EIA or other methods. The combination of performance, ...
... for Botox therapy and nerve block ... injectable needle has a precisely machined ... with an attached 61-cm (24-in) lead ... insertion. Single patient use only. A ...
... Back Relief Apron has standard ... the weight from the shoulders ... aid of a 6" wide ... strap keeps apron snug. Belts ...
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
Medicine Products: